LICENSE AGREEMENT BY AND BETWEEN ASTRAZENECA AB AND ARDELYX, INC. OCTOBER 4, 2012License Agreement • June 5th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • Delaware
This License Agreement (the “Agreement”) is entered into as of the 4th day of October, 2012 (the “Effective Date”) by and between AstraZeneca AB (publ), a Swedish corporation with corporate identity no. 556011-7482 and a place of business at 431 83 Mölndal, Sweden (“AstraZeneca”) and Ardelyx, Inc., a Delaware corporation having its principal place of business at 34175 Ardenwood Boulevard, Fremont, California United States of America 94555 (“Ardelyx”). Ardelyx and AstraZeneca are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE OPTION AND LICENSE AGREEMENT BY AND BETWEEN SANOFI AND ARDELYX, INC. DATED FEBRUARY 21, 2014License Option and License Agreement • June 5th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • New York
This License Option and License Agreement (the “Agreement”) is entered into as of the 21 day of February, 2014 (the “Effective Date”) by and between Sanofi, a French corporation with a place of business at 54, rue La Boétie, 75008 Paris, France (“Sanofi”) and Ardelyx, Inc., a Delaware corporation having its principal place of business at 34175 Ardenwood Boulevard, Fremont, California United States of America 94555 (“Ardelyx”). Ardelyx and Sanofi are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NUMBER ONE TO LICENSE AGREEMENT BY AND BETWEEN ASTRAZENECA AB AND ARDELYX, INC. DECEMBER 23, 2013License Agreement • June 5th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • Delaware
This Amendment Number One to License Agreement (“Amendment One”) is entered into as of the 23rd day of December, 2013 (the “Amendment One Effective Date”) by and between AstraZeneca AB (publ), a Swedish corporation with corporate identity no. 556011-7482 and a place of business at 431 83 Molndal, Sweden (“AstraZeneca”) and Ardelyx, Inc. a Delaware corporation having its principal place of business at 34175 Ardenwood Boulevard, Fremont, California United States of America 94555 (“Ardelyx”). Ardelyx and AstraZeneca are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
